Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

Hypoxia is prominent in solid tumors and a recognized driver of malignancy. Thus far, targeting tumor hypoxia has remained unsuccessful. Myo-inositol trispyrophosphate (ITPP) is a re-oxygenating compound without apparent toxicity. In preclinical models, ITPP potentiates the efficacy of subsequent ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Marcel A., Linecker, Michael, Fritsch, Ralph, Muehlematter, Urs J., Stocker, Daniel, Pestalozzi, Bernhard, Samaras, Panagiotis, Jetter, Alexander, Kron, Philipp, Petrowsky, Henrik, Nicolau, Claude, Lehn, Jean-Marie, Humar, Bostjan, Graf, Rolf, Clavien, Pierre-Alain, Limani, Perparim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217170/
https://www.ncbi.nlm.nih.gov/pubmed/34155211
http://dx.doi.org/10.1038/s41467-021-24069-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217170/
https://www.ncbi.nlm.nih.gov/pubmed/34155211
http://dx.doi.org/10.1038/s41467-021-24069-w

Ejemplares similares